Supplementary Figure 1 Emission spectra of carazolol bound to β_2 AR-T4L.



(a) Emission spectra of bound carazolol to the β_2 AR-T4L and (b) spectra of free carazolol in solution following complete receptor denaturation. Thirteen continuous emission spectra were obtained following 5 min incubations at temperatures ranging from 25 to 85 °C in 5 °C intervals. The 356 nm peaks were all normalized and the height of the 341 nm peaks (indicated by the dotted lines) were plotted as a function of temperature and normalized as illustrated in **Supplementary figure 2a**.

Supplementary Figure 2 Melting temperatures (T_m) of the β_2AR -T4L in MNG ampihphiles or conventional detergents.



(a) Temperature dependence of fluorescence peak ratio (341 nm/356 nm) of β_2 AR-T4L in the presence of detergents or amphiphiles at 10 × CMC. (b) T_m values of the receptor were plotted in terms of CMC of the MNG amphiphiles (MNG-1, MNG-2, and MNG-3) or conventional detergents (MPA-1, MPA-3, DM, DDM, and TDM). β_2 AR-T4L with bound carazolol (an inverse agonist) was incubated with various agents at the various concentrations at indicated temperatures for 5 min prior to fluorescence emission measurement as described in the Online Methods and in **Supplementary Figure 1**. Normalized results are expressed as mean ± s.e.m. (n = 3, 4, or 5).

Supplementary Figure 3 Thermal stability of Cytochrome bo_3 and CMP-Sia in MNG amphiphiles or conventional detergents using CPM assay.



CPM assays for (a) Cytochrome bo_3 , and (b) CMP-Sia with MNG amphiphiles (MNG-1, MNG-2, and MNG-3) or conventional detergents (MPA-4, DDM, DM and SDS). All agents were used at 10 × CMC. The unfolding of the each protein in various amphiphiles was monitored at 40 °C for 130 min using a microplate spectrofluorometer set at an excitation wavelength of 387 nm and an emission wavelength of 463 nm. Measurements were taken every 5 min after automatic agitation of the plate.

Supplementary Figure 4 Long-term solubility and activity of LeuT in MNG amphiphiles or conventional detergents.



Long-term (**a**) solubility and (**b**) activity ([³H]-Leu binding) assay for LeuT solubilized with MNG amphiphiles (MNG-1, MNG-2, and MNG-3) and conventional detergents (MPA-1, MPA-3, DDM, laurydimethylamine-N-oxide (LDAO) and *n*-octyl- β -D-glucopyranoside (OG)) at 10 × CMC except OG, which was tested at 2 × CMC. (**c**) LeuT solubility in MNG amphiphiles or DDM at 0.026 wt % above each CMC. LeuT concentrations and activities were monitored at indicated time points for protein stored at the room temperature. Protein concentration was measured by UV-visible spectroscopy and activity was evaluated using a scintillation proximity assay (SPA). Results are expressed as % concentration or % activity relative to the appropriate day 0 measurement. Normalized results are expressed as mean ± s.e.m. (*n* = 2).

Supplementary Figure 5 Absorption spectra of LHI-RC complex solubilized with MNG amphiphiles or conventional detergents.



Spectroscopic comparison of LHI-RC complex from *Rhodobacter Capsulatus* solubilized with (**a**) MNG amphiphiles (MNG-1, MNG-2, and MNG-3) and (**b**) conventional detergents (MPA-3, DDM, laurydimethylamine-N-oxide (LDAO), and *n*-octyl- β -D-glucopyranoside (OG)). All amphiphiles or detergents were used at 1.0 wt % except OG, which was tested at 2.0 wt %.

Supplementary Figure 6 Absorption spectra of LHI-RC complex purified with MNG amphiphiles or conventional detergents.



Spectroscopic comparison of LHI-RC complex from *Rhodobacter Capsulatus* purified with (**a**) MNG amphiphiles (MNG-1, MNG-2, and MNG-3) and (**b**) conventional detergents (MPA-3, DDM, LDAO, and OG). The complex was purified with the amphiphiles or detergents at $1 \times CMC$ at room temperature.

Supplementary Figure 7 Long-term stability of LHI-RC complex in MNG amphiphiles or conventional detergents.



All agents were tested at (**a**) CMC + 0.017 wt %, (**b**) 0.2 wt %, (**c**) 1.0 wt % and (**d**) CMC + 0.34 mM. The absorption ratios (A_{875}/A_{680}) of the protein samples were followed as a function of time at room temperature.

Supplementary Figure 8 Biochemical characterization of membrane proteins extracted with amphiphilic agents from the native membranes.



(a) Activity of wild-type β_2AR extracted with MNG-3, DDM, or TDM at 1% or 2% from an insect cell membrane. Results are expressed as mean \pm s.d. (n = 3). (b) Competition [³H]-Leu/Leu binding curves for LeuT extracted and purified with MNG-3 and DDM from a bacterial membrane. Normalized results are expressed as mean \pm s.e.m. (n = 2). (c) Fluorescent size exclusion chromatography (FSEC) analysis of CMP-Sia-GFP fusion protein after solubilization with 1% MNG-3 or 1% DDM from a yeast membrane.

Supplementary Figure 9 SDS-PAGE of wheat germ CF translation of the proteins in the presence of MNG amphiphiles or conventional detergents.



SDS-PAGE of wheat germ CF translation of (a) green fluorescent protein (GFP) and (b) bacterioopsin (BO) in the presence of MNG amphiphiles (MNG-1, MNG-2, and MNG-3) and conventional detergents (MPA-1, MPA-3, DDM, and DM). The agents were used at 0.1 wt % or 0.2 wt %. Arrows indicate the location of GFP and BO protein bands in SDS-PAGE. "S" and "P" represent supernatant and pellet fractions of protein samples after centrifugation. GFP study showed that CF expression is not inhibited by any of the conventional detergents at 0.1 wt %, but significant inhibition is observed at 0.2 wt % of each detergent. The three MNG amphiphiles did not inhibit GFP expression even at 0.2 wt %. CF expression of a membrane protein, BO, showed that expression of the protein was inhibited in the presence of the conventional detergents at 0.2 wt % (DDM is the best of the conventional detergents). These detergents at 0.1 wt % did not effectively solubilize the BO, most of which was found in an aggregated form. In contrast, 0.2 wt % MNG-1 or MNG-2 did not cause any inhibition of BO expression, as seen with GFP, and these amphiphiles efficiently solubilized the BO that was produced. The behavior of MNG-3 was slightly different. Even at 0.1 wt %, this MNG amphiphile was reasonably effective at solubilizing the BO produced, but 0.2 wt % MNG-3 seemed to reduce BO expression slightly (all expressed protein was soluble).

| | Melting temperatures (T _m) of carazolol bound β_2 AR-T4L at various critical micelle concentrations (CMC) measured in $^{\circ}$ C | | | | | | |
|-------|--|----------------------------------|----------------------------------|---------------------------------|---------------------------------|----------------------------------|----------------|
| | 1.5x CMC T _m ± SEM | 3.5x CMC T _m ± SEM | 6.5x CMC T _m ± SEM | 10x CMC T _m ± SEM | 50x CMC T _m ± SEM | 250x CMC T _m ± SEM | ΔT_{m} |
| DDM | 62.0 ± 0.23 (n=5) | 64.2 ± 0.06 (n=4) | $64.4 \pm 0.14 (n=4)$ | 63.5 ± 0.16 (n=4) | 63.0 ± 0.08 (n=4) | 62.2 ± 0.22 (n=4) | |
| TDM | n.d. | n.d. | n.d. | 63.2 ± 0.28 (n=3) | 63.5 \pm 0.34 (n=3) | 63.2 ± 0.24 (n=3) | -0.9 |
| DM | $58.2 \pm 0.29 (n=3)$ | 56.0 ± 0.33 (n=3) | n.d. | 55.4 ± 0.63 (n=4) | 56.0 ± 0.64 (n=3) | n.d. | -6.2 |
| MPA-1 | n.d. | n.d. | n.d. | 51.4 \pm 0.21 (n=3) | n.d. | n.d. | -13.0 |
| MPA-3 | n.d. | n.d. | n.d. | 58.8 \pm 0.14 (n=3) | 58.3 ± 0.10 (n=3) | n.d. | -5.6 |
| MNG-1 | n.d. | n.d. | n.d. | 65.1 \pm 0.25 (n=3) | 65.1 \pm 0.14 (n=3) | 64.2 ± 0.21 (n=3) | +0.7 |
| MNG-2 | n.d. | n.d. | n.d. | 64.6 ± 0.37 (n=3) | 67.1 \pm 0.10 (n=3) | 67.0 ± 0.31 (n=3) | +2.7 |
| MNG-3 | n.d. | n.d. | n.d. | 67.4 ± 0.06 (n=3) | 68.4 ± 0.09 (n=3) | 66.8 ± 0.15 (n=3) | +4.0 |

Supplementary Table 1 Melting Temperatures (T_m) of carazolol bound β_2 adrenergic receptor (β_2AR -T4L) at various critical micelle concentrations (CMC) measured in °C.

The highest T_m value obtained for each amphiphiles is shown in bold and used to calculate ΔT_m relative to DDM.

The highest T_m value obtained for each amphiphile is shown in bold and used to calculated ΔT_m relative to DDM. n.d. = <u>n</u>ot <u>d</u>etermined; n = number of replicates.

Supplementary Table 2 Crystal data collection statistics for cytochrome $b_6 f/MNG-3$ complex.

| Space group | I222 | | | |
|--|-------------------|--|--|--|
| Unit cell dimension (Å) | 102.1 169.3 352.6 | | | |
| Number of reflections | 195299 | | | |
| Number of unique reflections | 39941 | | | |
| Resolution limits (Å) | 44.03 - 3.47 | | | |
| Higher resolution shell (Å) | (3.68 - 3.47) | | | |
| Completness | 99.6% (99.2%) | | | |
| Redundancy | 4.9 | | | |
| R _{merged} | 8.69% (59.9%) | | | |
| R _{measured} | 9.7% (67.1%) | | | |
| $I/\sigma(I)$ | 13.8 (2.6) | | | |
| | | | | |
| Crystallographic refinement statistics | | | | |
| Resolution range (Å) | 39.97 - 3.47 | | | |
| Number of reflections | 39850 | | | |
| R / FreeR | 0.1937 / 0.2334 | | | |
| Number of atoms (total) | 7821 | | | |
| Mean B value ($Å^2$) | 112.60 | | | |
| rms deviation from ideal values: | | | | |
| bond length (Å) | 0.010 | | | |
| bond angle (degree) | 1.20 | | | |
| | | | | |





Synthetic route for MNG amphiphiles (MNG-1, MNG-2, and MNG-3): (a) undecanoic acid, EDC • HCl, HOBt, room temperature; (b) perbenzoylated maltosylbromide (2.1 equiv.), AgOTf, CH_2Cl_2 , – 45 °C \rightarrow room temperature; (c) NaOMe, MeOH, room temperature; (d) decanol, NaH, DMF, 120 °C; (e) *p*-TSA, MeOH, room temperature; (f) NaH, decyl iodide, THF, room temperature; (g) LiAlH₄, THF, room temperature.

General procedure for glycosylation reactions

This reaction was performed according to a literature method¹ with slight modification. A mixture of alcohol derivative, AgOTf (2.4 equiv.), 2,4,6-collidine (1.8 equiv.) in anhydrous CH_2Cl_2 (40 mL) was stirred at – 45 °C. A solution of perbenzoylated maltosylbromide (2.4 equiv.) in CH_2Cl_2 (40 mL) was added dropwise over 0.5 h to this suspension. Stirring was continued for 0.5 h at -45 °C, and then the reaction mixture was allowed to warm to 0 °C and left stirring for 1.5 h. After completion of reaction (as detected by TLC), pyridine was added to the reaction mixture, and it was diluted with CH_2Cl_2 (40 mL) before being filtered over celite. The filtrate was washed successively with a 1 M aqueous $Na_2S_2O_3$ solution (40 mL), a 0.1 M aqueous HCl solution (40 mL), and brine (2 × 40 mL). Then the organic layer was dried with anhydrous Na_2SO_4 and the solvents were removed by rotary evaporation.

The residue was purified by silica gel column chromatography (EtOAc/hexane) providing desired product as a glassy solid.

General Procedure for the de-O-benzoylations under Zemplén's conditions¹

The *O*-benzoylated compounds were dissolved in MeOH and then treated with the required amount of a methanolic solution of 0.5 M NaOMe such that the final concentration of NaOMe was 0.05 M. The reaction mixture was left stirring for 6 h at room temperature, and then neutralized with Amberlite IR-120 (H⁺ form) resin. The resin was removed by filtration and washed with MeOH and solvent was removed from the combined filtrate *in vacuo*. The residue was purified by silica gel column chromatography (MeOH/CH₂Cl₂). Further purification carried out by recrystallization using CH₂Cl₂/MeOH/diethyl ether afforded fully de-*O*-benzoylated product as a white solid.

Synthesis and characterization of MNG amphiphiles

Scheme 1



(a) undecanoic acid, EDC • HCl, HOBt, room temperature, 91%; (b) (g) perbenzoylated maltosylbromide (2.4 equiv.), AgOTf, CH₂Cl₂, – 45 °C \rightarrow room temperature, 92%; (c) NaOMe, MeOH, room temperature, 95%.

Undecanoic acid (2,2-bis-hydroxymethyl-3-undecanolylamino-propyl)-amide (2)

This compound was synthesized according to **scheme 1**. 2,2-bis-aminomethyl-propane-1,3-diol $(1)^2$ (0.51 g, 3.8 mmol), undecanoic acid (1.42 g, 7.6 mmol), 1-hydroxybenzotriazole monohydrate (HOBt) (1.2 g, 9.1 mmol) was dissolved in anhydrous DMF (30 mL). 1-(3-(dimethylamino)propyl)-3-ethylcarbodiimide hydrochoride (EDC • HC1) (1.7 g, 0.91 mmol) was added in small portions at 0 °C and the resulting solution left stirring at room temperature for 20 hr. The solution was taken up with

EtOAc (100 mL) and was washed successively with a 1 M aqueous NaHCO₃ solution (100 mL), a 0.1 M aqueous HCl solution (100 mL) and brine (2 × 100 mL). Then the organic layer was dried with anhydrous Na₂SO₄ and the solvent was removed by rotary evaporation. The reaction mixture was precipitated with ether (100 mL) and the resulting solid was collected and dried *in vacuo* to afford amide-containing diol (**2**) as a white solid (1.63 g, 91%). This product was used for next reaction without further purification. ¹H NMR (300 MHz, CDCl₃): δ 6.97 (t, *J* = 6.8 Hz, 2H), 4.65 (t, *J* = 6.6 Hz, 2H), 3.27 (d, *J* = 7.0 Hz, 4H), 3.01 (d, *J* = 7.0 Hz, 4H), 2.25 (t, *J* = 7.4 Hz, 2H), 1.64 (quin, 4H), 1.30-1.23 (m, 28H), 1.38-1.21 (m, 6H), 0.88 (t, *J* = 7.0 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 176.1, 61.0, 46.6, 38.3, 36.9, 32.1, 29.8, 29.7, 29.5, 26.2, 22.9, 14.3; HRMS (ESI): calcd. for C₂₇H₅₄N₂O₄ [M]⁺ 471.4157, found 471.4154.

MNG-1a was synthesized according to the general procedure for glycosylation. ¹**H NMR** (300 MHz, CDCl₃): δ 8.07 (d, J = 8.4 Hz, 4H), 8.02-7.85 (m, 12H), 7.87 (d, J = 8.4 Hz, 4H), 7.80 (d, J = 8.4 Hz, 4H), 7.74 (d, J = 8.4 Hz, 4H), 7.65-7.20 (m, 42H), 6.22-6.15 (m, 2H), 6.12 (t, J = 10.0 Hz, 2H), 5.70 (d, J = 4.1 Hz, 2H), 5.66 (t, J = 10.0 Hz, 2H), 5.32 (t, J = 9.4 Hz, 2H), 5.17 (dd, J = 10.0, 3.5 Hz, 2H), 5.06 (dd, J = 10.0, 8.0 Hz, 2H), 4.75 (d, J = 10.0 Hz, 2H), 4.57 (dd, J = 12.7, 3.2 Hz, 2H), 4.40-4.27 (m, 5H), 4.18 (dd, J = 13.1, 4.4 Hz, 2H), 3.53 (d, J = 9.6 Hz, 2H), 3.39 (m, 2H), 3.21 (d, J = 8.0 Hz, 2H), 3.06 (m, 4H), 2.91 (dd, J = 13.6, 3.0 Hz, 2H), 2.26 (t, J = 7.5 Hz, 4H), 1.6 (br s, 4H), 1.35-1.15 (br s, 28H), 0.86 (t, J = 6.9 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 174.1, 166.2, 166.0, 165.9, 165.6, 165.4, 165.2, 165.1, 134.3, 133.8, 133.6, 133.5, 133.4, 133.3, 130.2, 130.1, 129.9, 129.8, 129.7, 129.5, 129.4, 129.2, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 101.3, 95.9, 74.3, 72.8, 72.1, 71.4, 69.9, 69.3, 69.1, 62.7, 42.2, 42.0, 36.6, 32.0, 29.8, 29.7, 29.5, 26.0, 22.9, 14.3; **MS** (MALDI-TOF): calcd. for C₁₄₉H₁₅₀N₂O₃₈Na [M+Na]⁺ 2597.9759, found 2597.9653.

MNG-1 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.20 (d, *J* = 3.8 Hz, 2H), 4.34 (d, *J* = 7.9 Hz, 2H), 3.96-3.80 (m, 8H), 3.73-3.63 (m, 9H), 3.60-3.39 (m, 10H), 3.38-3.22 (m, 7H), 2.27 (t, *J* = 6.6 Hz, 4H), 1.65 (br t, 4H), 1.42-1.25 (br s, 28H), 0.93 (t, *J* = 6.8 Hz, 6H); ¹³**C NMR** (75 MHz, CD₃OD): δ 177.1, 104.8, 103.1, 81.4, 77.9, 76.8, 75.2, 74.9, 74.8, 74.3, 71.7, 71.3, 62.9, 62.2, 45.9, 41.0, 37.5, 33.2, 30.9, 30.8, 30.6, 30.5, 27.2, 23.9, 14.6; **HRMS (ESI)**: calcd. for C₅₁H₉₄N₂O₂₄Na [M+Na]⁺ 1141.6089, found 1141.6071.

Scheme 2



(d) decanol, NaH, DMF, 120 °C; (e) *p*-TSA, MeOH, room temperature, 92% (in two steps); (b) perbenzoylated maltosylbromide (2.4 equiv.), AgOTf, CH₂Cl₂, -45 °C \rightarrow room temperature, 93%; (c) NaOMe, MeOH, room temperature, 96%.

2,2-Bis-decyloxymethyl-propane-1,3-diol (4)

This compound was synthesized according to scheme 2. To a solution of decanol (3.3 g, 17 mmol) in DMF (40 mL) was added NaH (0.69 g, 0.17 mmol, 60%) at 0 °C. The mixture was stirred at room temperature under N₂ atmosphere for 0.5 h. After addition of 5,5-bis-bromomethyl-2,2-dimethyl-[1,3]dioxane (3)³ (1.3 g, 4.3 mmol), the reaction mixture was warmed to 120 °C and stirred further for 15 hr. After cooling to room temperature, the reaction was quenched with ice-cold H_2O (100 mL) and extracted with ether (3×80 mL). The combined organic layer washed with brine (2×100 mL), dried with anhydrous Na₂SO₄ and then concentrated by rotary evaporation. To the residue dissolved in 1:1 mixture of CH₂Cl₂ and MeOH (120 mL) was added *p*-toluenesulfonic acid (*p*-TSA) monohydrate (300 mg) and left stirring at room temperature for 2 hr. After the neutralization of the reaction mixture with a saturated aqueous NaHCO₃ solution, the volume of solvent was reduced by rotary evaporation. The residue was partitioned between CH₂Cl₂ and water. The separated organic layer was washed with brine, dried with anhydrous Na₂SO₄, and then concentrated in vacuo. Flash column chromatography (EtOAc/hexane) affords ether-containing diol (4) as a white solid (1.89 g, 92% (two steps)). ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3)$: δ 3.64 (d, J = 6.4 Hz, 4H), 3.51 (s, 4H), 3.42 (t, J = 6.3 Hz, 4H), 2.87 (t, J = 6.3 Hz, 4H), 3.51 (s, 4H), 3.51 Hz, 2H), 1.56 (quin, J = 6.7 Hz, 4H), 1.26 (br s, 28H), 1.38-1.21 (m, 28H), 0.88 (t, J = 6.8 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 73.4, 72.3, 71.1, 65.7, 44.7, 32.1, 29.8, 29.7, 29.6, 29.5, 26.4, 22.9, 14.3; **HRMS (ESI)**: calcd. for C₂₅H₅₂O₄Na [M+Na]⁺ 439.3758, found 439.3778.

MNG-2a was synthesized according to the general procedure for glycosylation. ¹**H NMR** (300 MHz, CDCl₃): δ 8.07 (d, J = 8.4 Hz, 4H), 8.02-7.95 (m, 8H), 7.91 (d, J = 8.4 Hz, 4H), 7.87 (d, J = 8.4 Hz, 4H), 7.80 (d, J = 8.4 Hz, 4H), 7.74 (d J = 8.4 Hz, 4H), 7.65-7.20 (m, 42H), 6.12 (t, J = 9.8 Hz, 2H), 5.68 (d, J = 4.5 Hz, 2H), 5.65 (t, J = 9.4 Hz, 2H), 5.40 (t, J = 9.8 Hz, 2H), 5.22-5.10 (m, 4H), 4.65-4.55 (m, 4H), 4.38-4.13 (m, 8H), 3.70 (d, J = 9.2 Hz, 2H), 3.46 (d, J = 8.0 Hz, 2H), 3.35-3.15 (m, 8H), 2.97 (t, J = 9.4 Hz, 4H), 1.40 (br s, 4H), 1.33-1.12 (br s, 30H), 0.87 (t, J = 7.0 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 166.3, 166.0, 165.9, 165.7, 165.2, 165.0, 133.9, 133.6, 133.5, 133.4, 133.3, 130.3, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7, 129.6, 129.5, 129.3, 129.2, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 101.1, 95.9, 74.8, 72.4, 72.3, 71.7, 71.5, 69.9, 69.2, 69.1, 68.9, 68.6, 63.5, 62.7, 45.0, 32.1, 29.8, 29.7, 29.5, 26.2, 22.9, 14.3; **MS (MALDI-TOF)**: calcd. for C₁₄₇H₁₄₈O₃₈Na [M+Na]⁺ 2543.9541, found 2543.9468.

MNG-2 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.19 (d, *J* = 3.8 Hz, 2H), 4.36 (d, *J* = 7.9 Hz, 2H), 3.98-3.80 (m, 8H), 3.77-3.67 (m, 12H), 3.55-3.23 (m, 20H), 1.58 (br m, 4H), 1.45-1.30 (br s, 28H), 0.94 (t, *J* = 6.8 Hz, 6H); ¹³**C NMR** (75 MHz, CD₃OD): δ 105.2, 103.1, 81.5, 78.0, 76.7, 75.2, 75.0, 74.9, 74.3, 72.8, 71.6, 62.9, 46.7, 33.2, 31.0, 30.9, 30.8, 30.7, 27.6, 23.9, 14.6; **HRMS (ESI)**: calcd. for C₄₉H₉₂O₂₄Na [M+Na]⁺ 1087.5871, found 1087.5876.

Scheme 3



(f) NaH, decyl iodide, THF, room temperature; (g) LiAlH₄, THF, room temperature, 93% (in two steps); (b) perbenzoylated maltosylbromide (2.4 equiv.), AgOTf, 2,4,6-Collidine, CH₂Cl₂, – 45 °C \rightarrow room temperature, 90%; (c) NaOMe, MeOH, room temperature, 94%.

2,2-Bis-decyl-propane-1,3-diol (6)

This compound was synthesized according to a literature method⁴ (scheme 3) with slight modification. To a solution of diethyl malonate (5) (1.04 mL, 6.9 mmol) in THF (40 mL) was added dropwise a solution of NaH (0.82g, 21 mmol) in THF at 0 °C and left stirring for 20 min. After addition of iododecane (3.8 mL, 18 mmol), the reaction mixture was stirred at room temperature for 24 hr, quenched by adding ice-cold saturated NH₄Cl (100 mL) and then extracted with diethyl ether (2 × 50 mL). The organic layer was washed with brine and dried with anhydrous Na₂SO₄. After complete evaporation of solvent, LiAlH₄ (0.52 g, 14.0 mmol) was added slowly to the residue dissolved in THF (50 mL) at 0 °C. The mixture was stirred at room temperature for 4 hr, quenched with MeOH, water, a 1 N aqueous HCl solution successively at 0 °C and then extracted with diethyl ether (2 × 50 mL). The combined organic layer was washed with brine and dried with anhydrous Na₂SO₄. The residue was purified by silica gel column chromatography (EtOAc/hexane) providing alkyl-containing diol (6) as a white solid (2.3 g, 93% (two steps)). ¹H NMR (300 MHz, CDCl₃): δ 3.55 (s, 4H), 2.55 (s, 2H), 1.38-1.08 (m, 36H), 0.88 (t, *J* = 6.8 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 69.6, 41.2, 32.1, 31.0, 30.8, 29.9, 29.8, 29.6, 23.1, 22.9, 14.3; HRMS (ESI): calcd. for C₂₃H₄₈O₂Na [M+Na]⁺ 379.3547, found 379.3546.

MNG-3a was synthesized according to the general procedure for glycosylation. ¹**H NMR** (300 MHz, CDCl₃): δ 8.05 (d, J = 8.4 Hz, 4H), 8.02-7.95 (m, 8H), 7.92 (d, J = 8.4 Hz, 4H), 7.86 (d, J = 8.4 Hz, 2H), 5.68–5.58 (m, 4H), 5.34 (t, J = 10.2 Hz, 2H), 5.18-5.06 (m, 4H), 4.68-4.52 (m, 4H), 4.38-4.16 (m, 8H), 3.32 (d, J = 7.6 Hz, 2H), 2.94-2.86 (m, 2H), 2.70 (d, J = 8.6 Hz, 2H), 1.35-0.98 (m, 34H), 0.87 (t, J = 6.9 Hz, 6H); ¹³C NMR (75 MHz, CDCl₃): δ 166.3, 166.0, 165.7, 165.3, 165.2, 165.0, 133.9, 133.7, 133.6, 133.4, 133.3, 130.3, 130.1, 130.0, 129.9, 129.8, 129.7, 129.6, 129.4, 129.2, 129.0, 128.9, 128.8, 128.6, 128.5, 95.9, 74.5, 72.3, 72.2, 71.5, 69.2, 62.8, 40.4, 32.1, 30.6, 30.3, 29.9, 29.8, 29.7, 29.6, 22.9, 22.3, 14.3; **MS (MALDI-TOF)**: calcd. for C₁₄₅H₁₄₄O₃₆Na [M+Na]⁺ 2483.9330, found 2483.928.

MNG-3 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.18 (d, *J* = 3.8 Hz, 2H), 4.39 (d, *J* = 7.9 Hz, 2H), 3.98-3.78 (m, 4H), 3.77-3.60 (m, 6H), 3.58-3.23 (m, 20H), 1.58 (br m, 6H), 1.42-1.16 (br s, 34H), 0.93 (t, *J* = 6.8 Hz, 6H); ¹³**C NMR** (75 MHz, CD₃OD): δ 105.1, 103.0, 78.0, 76.6, 74.9, 74.8, 71.6, 42.2, 33.2, 31.7, 30.9, 30.8, 30.6, 23.9, 14.6; **HRMS (ESI**): calcd. for C₄₇H₈₈O₂₂Na [M+Na]⁺ 1027.5660, found 1027.5653.

Synthesis and characterization of monopod amphiphiles (MPAs)





(b) perbenzoylated maltosylbromide (1.2 equiv.), AgOTf, CH_2Cl_2 , - 45 °C \rightarrow room temperature, 95% (MPA-1a), 95% (MPA-2a), 94% (MPA-3a), 93% (MPA-4a); (c) NaOMe, MeOH, room temperature, 96% (MPA-1 and MPA-2), 95% (MPA-3 and MPA-4).

Undecanonic acid (2-hydroxy-ethyl)-amide (7) & undecanonic acid (2-hydroxy-propyl)-amide (8) These compounds were synthesized according to the synthetic protocol for the preparation of amidecontaining diol (2) using 1.1 equivalent of 2-aminoethanol and 3-amino-propan-1-ol with undecanoic acid, respectively.

Undecanonic acid (2-hydroxy-ethyl)-amide (7), Yield: 95%; ¹H NMR (300 MHz, CDCl₃): δ 6.14 (br s, 1H), 3.72 (q, *J* = 5.0 Hz, 2H), 3.42 (q, *J* = 5.4 Hz, 2H), 3.16 (t, *J* = 5.1 Hz, 1H), 2.21 (t, *J* = 7.6 Hz, 2H), 1.63 (quin, *J* = 7.0 Hz, 2H), 1.38-1.20 (m, 14H), 0.88 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 174.8, 62.7, 42.6, 36.9, 32.1, 29.8, 29.7, 29.5, 25.9, 22.9, 14.3; HRMS (ESI): calcd. for C₁₃H₂₇NO₂ [M]⁺ 229.2037, found 229.2043.

Undecanonic acid (2-hydroxy-propyl)-amide (8), Yield: 93%; ¹H NMR (300 MHz, CDCl₃): δ 6.25 (br s, 1H), 3.67 (quin, J = 6.0 Hz, 4H), 3.62 (q, J = 5.6 Hz, 2H), 3.40 (q, J = 6.2 Hz, 2H), 2.19 (t, J = 7.4 Hz, 2H), 1.72-1.56 (m, 4H), 1.36-1.20 (m, 14H), 0.88 (t, J = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 174.9, 59.3, 36.9, 36.3, 32.5, 32.1, 29.7, 29.6, 29.5, 29.4, 26.0, 22.8, 14.3; **HRMS (ESI**): calcd. for C₁₄H₂₉NO₂ [M]⁺ 243.2193, found 243.2188.

MPA-1a was synthesized according to the general procedure for glycosylation. ¹**H NMR** (300 MHz, CDCl₃): δ 8.09 (d, J = 8.3 Hz, 2H), 7.99 (d, J = 8.4 Hz, 2H), 7.92-7.83 (m, 4H), 7.78-7.67 (m, 4H), 7.65-7.17 (m, 23H), 6.10 (t, J = 10.2 Hz, 1H), 5.85-5.73 (m, 3H), 5.67 (t, J = 9.8 Hz, 1H), 5.35-5.22 (m, 2H), 4.97 (dd, J = 12.3, 2.5 Hz, 1H), 4.79 (dd, J = 12.2, 3.2 Hz, 2H), 4.55-4.45 (m, 3H), 4.34-4.25 (dd, J = 12.9, 3.8 Hz, 1H), 4.15-4.07 (m, 1H), 3.92-3.83 (m, 1H), 3.66 (td, J = 10.4, 4.0 Hz, 1H), 3.55-3.43 (m, 1H), 3.36-3.23 (m, 1H), 1.91-1.81 (m, 2H), 1.42 (quin, J = 7.2 Hz, 2H), 1.35-1.05 (m, 14H), 0.88 (t, J = 7.1 Hz, 3H); ¹³**C NMR** (75 MHz, CDCl₃): δ 173.3, 166.3, 166.0, 165.8, 165.6, 165.5, 165.3, 165.2, 133.8, 133.6, 133.5, 133.3, 130.2, 130.1, 130.0, 129.9, 129.8, 129.7, 129.5, 129.2, 128.9, 128.8, 128.6, 128.4, 128.3, 101.2, 96.7, 74.8, 73.4, 72.6, 71.1, 69.6, 69.4, 69.3, 63.5, 62.7, 39.1, 36.6, 32.1, 29.8, 29.7, 29.5, 29.4, 29.3, 25.7, 22.9, 14.3; **HRMS** (**ESI**): calcd. for C₇₄H₇₅NO₁₉Na [M+Na]⁺ 1304.4826, found 1304.4805.

MPA-2a was synthesized according to the general procedure for glycosylation. ¹**H NMR** (300 MHz, CDCl₃): δ 8.09 (d, J = 8.3 Hz, 2H), 7.99 (d, J = 8.4 Hz, 2H), 7.92-7.83 (m, 4H), 7.78-7.67 (m, 4H), 7.65-7.17 (m, 23H), 6.11 (t, J = 10.2 Hz, 1H), 5.95 (t, J = 5.6 Hz, 1H), 5.85-5.75 (m, 2H), 5.68 (t, J = 9.8 Hz, 1H), 5.34-5.24 (m, 2H), 5.00 (dd, J = 12.3, 2.5 Hz, 1H), 4.80-4.71 (m, 2H), 4.56-4.45 (m, 3H), 4.31 (dd, J = 12.9, 3.8 Hz, 1H), 4.15-4.05 (m, 1H), 4.01-3.90 (m, 1H), 3.62-3.53 (m, 1H), 3.35-3.23 (m, 1H), 3.21-3.08 (m, 1H), 2.10 (t, J = 7.0 Hz, 2H), 1.82-1.63 (m, 2H), 1.62-1.50 (m, 2H), 1.35-1.18 (m, 14H), 0.86 (t, J = 7.0 Hz, 3H); ¹³**C NMR** (75 MHz, CDCl₃): δ 173.4, 166.3, 166.0, 165.8, 165.6, 165.5, 165.2, 165.1, 133.7, 133.6, 133.5, 133.4, 133.2, 130.1, 130.0, 129.9, 129.8, 129.7, 129.6, 129.1, 129.0, 128.9, 128.8, 128.6, 128.5, 128.4, 128.3, 128.2, 101.0, 96.7, 74.8, 73.5, 72.6, 71.1, 69.4, 69.3, 68.8, 63.4, 62.7, 37.1, 36.7, 32.0, 29.7, 29.6, 29.5, 29.4, 29.3, 29.2, 26.0, 22.8, 14.3; **HRMS (ESI)**: calcd. for C₇₅H₇₇NO₁₉Na [M+H]⁺ 1296.5163, found 1296.5222.

MPA-1 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.15 (d, *J* = 3.4 Hz, 1H), 4.29 (d, *J* = 7.8 Hz, 1H), 3.97-3.75 (m, 4H), 3.73-3.54 (m,

5H), 3.54-3.20 (m, 7H), 2.19 (t, J = 7.5 Hz, 2H), 1.59 (br quin, 2H), 1.29 (br s, 14H), 0.89 (t, J = 6.8 Hz, 3H); ¹³**C NMR** (75 MHz, CD₃OD): δ 176.6, 104.6, 103.1, 81.5, 77.9, 76.8, 75.2, 74.9, 74.8, 74.3, 71.6, 69.9, 62.9, 40.7, 37.3, 33.2, 30.9, 30.8, 30.6, 30.5, 27.2, 23.9, 14.6; **HRMS (ESI)**: calcd. for C₂₅H₄₇NO₁₂Na [M+Na]⁺ 576.2991, found 576.2964.

MPA-2 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.21 (d, *J* = 3.8 Hz, 1H), 4.32 (d, *J* = 7.7 Hz, 1H), 3.99-3.76 (m, 4H), 3.75-3.56 (m, 5H), 3.56-3.23 (m, 7H), 2.22 (t, *J* = 7.0 Hz, 2H), 1.83 (quin, *J* = 6.2 Hz, 2H), 1.64 (br quin, 2H), 1.33 (br s, 14H), 0.94 (t, *J* = 6.9 Hz, 3H); ¹³**C NMR** (75 MHz, CD₃OD): δ 176.5, 104.4, 103.0, 81.5, 77.9, 76.7, 75.2, 74.9, 74.9, 74.8, 74.3, 71.6, 68.5, 62.9, 62.3, 37.6, 37.3, 33.2, 30.8, 30.7, 30.6, 30.5, 30.4, 27.2, 23.9, 14.6; **HRMS (ESI)**: calcd. for C₂₆H₄₉NO₁₂Na [M+Na]⁺ 568.3328, found 568.3345.

2-decyloxy-ethanol (9) & 3-decyloxy-propan-1-ol (10)

These were synthesized according to a literature method⁵.

2-decyloxy-ethanol (**9**); ¹H and ¹³C NMR spectra of **9** are in good agreement with the previously reported spectra; **HRMS (ESI)**: calcd. for $C_{12}H_{26}O_2Na [M+H]^+ 203.2007$, found 203.2011. **3-decyloxy-propan-1-ol** (**10**); ¹H and ¹³C NMR spectra of **10** are in good agreement with the previously reported spectra; **HRMS (ESI)**: calcd. for $C_{13}H_{28}O_2Na [M+H]^+ 217.2163$, found 217.2171. **MPA-3a** was synthesized according to the general procedure for glycosylation. ¹H NMR (300 MHz, CDCl₃): δ 8.10 (d, *J* = 8.4 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 2H), 7.90-7.83 (m, 4H), 7.74 (d, *J* = 8.4 Hz, 4H), 7.65 (d, *J* = 8.4 Hz, 2H), 7.61-7.10 (m, 2H), 6.10 (t, *J* = 10.0 Hz, 1H), 5.82-5.70 (m, 2H), 5.66 (t, *J* = 9.9 Hz, 1H), 5.36-5.23 (m, 2H), 5.00-4.88 (m, 2H), 4.75 (dd, *J* = 12.0, 4.1 Hz, 1H), 4.55-4.37 (m, 3H), 4.28 (dd, *J* = 12.4, 3.6 Hz, 1H), 4.15-4.07 (m, 1H), 4.00-3.89 (m, 1H), 3.56-3.42 (m, 2H), 3.25 (t, *J* = 6.8 Hz, 2H), 1.42-1.06 (m, 14H), 0.87 (t, *J* = 6.9 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃): δ 166.3, 166.0, 165.8, 165.6, 165.5, 165.4, 165.2, 133.7, 133.6, 133.5, 133.4, 133.3, 133.2, 130.1, 130.0, 129.9, 129.8, 129.7, 129.6, 129.5, 129.1, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.2, 101.0, 96.6, 75.2, 73.5, 73.1, 72.5, 71.8, 71.1, 70.1, 69.9, 69.4, 69.3, 63.8, 62.7, 32.1, 29.8, 29.7, 29.6, 29.5, 26.1, 22.9, 14.3; **HRMS (ESI)**: calcd. for $C_{73}H_74O_{19}Na$ [M+Na]⁺ 1277.4717, found 1277.4775.

MPA-4a was synthesized according to the general procedure for glycosylation. ¹H NMR (300 MHz, CDCl₃): δ 8.10 (d, *J* = 8.4 Hz, 2H), 7.99 (d, *J* = 8.4 Hz, 2H), 7.90-7.83 (m, 4H), 7.74 (d, *J* = 8.4 Hz, 2H), 7.91 (d, J) (d, J

4H), 7.65 (d, J = 8.4 Hz, 2H), 7.61-7.10 (m, 2H), 6.10 (t, J = 10.0 Hz, 1H), 5.82-5.70 (m, 2H), 5.66 (t, J = 9.9 Hz, 1H), 5.36-5.23 (m, 2H), 4.92 (dd, J = 12.0, 2.6 Hz, 1H), 4.81-4.70 (m, 2H), 4.55-4.37 (m, 3H), 4.27 (dd, J = 12.4, 3.6 Hz, 1H), 4.15-4.05 (m, 1H), 4.00-3.92 (m, 1H), 3.67-3.56 (m, 1H), 3.27 (t, J = 6.0 Hz, 2H), 3.18-3.03 (m, 2H), 1.82-1.68 (m, 2H), 1.39 (quin, J = 6.8 Hz, 2H), 1.34-1.10 (m, 12H), 0.88 (t, J = 7.0 Hz, 3H); ¹³**C NMR** (75 MHz, CDCl₃): δ 166.4, 166.0, 165.8, 165.6, 165.3, 165.2, 133.7, 133.6, 133.5, 133.4, 133.3, 133.2, 130.2, 130.1, 130.0, 129.9, 129.7, 129.6, 129. 5, 129.1, 129.0, 128.9, 128.8, 128.7, 128.6, 128.5, 128.4, 128.3, 101.0, 96.6, 75.1, 73.4, 73.1, 72.5, 71.2, 71.1, 70.1, 69.3, 67.4, 67.1, 63.7, 62.7, 32.1, 30.0, 29.8, 29.7, 29.6, 29.5, 26.2, 22.9, 14.3; **HRMS (ESI)**: calcd. for C₇₄H₇₆O₁₉Na [M+Na]⁺ 1291.4874, found 1291.4838.

MPA-3 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.20 (d, J = 3.7 Hz, 1H), 4.36 (d, J = 8.0 Hz, 1H), 4.18-4.00 (m, 1H), 3.97-3.82 (m, 3H), 3.82-3.60 (m, 8H), 3.58-3.47 (m, 4H), 3.45-3.38 (m, 1H), 3.37-3.26 (m, 2H), 1.62 (br quin, 2H), 1.34 (br s, 14H), 0.94 (t, J = 7.0 Hz, 3H); ¹³**C NMR** (75 MHz, CD₃OD): δ 104.5, 103.1, 81.4, 77.8, 76.8, 75.2, 74.9, 74.8, 74.3, 72.6, 71.6, 71.2, 69.8, 62.9, 62.3, 40.7, 33.2, 30.9, 30.8, 30.7, 30.6, 27.3, 23.9, 14.6; **HRMS (ESI)**: calcd. for C₂₁H₄₁NO₇Na [M+Na]⁺ 442.2781, found 442.2776.

MPA-4 was synthesized according to the general procedure for de-*O*-benzoylation. ¹**H NMR** (300 MHz, CD₃OD): δ 5.20 (d, *J* = 3.7 Hz, 1H), 4.31 (d, *J* = 7.5 Hz, 1H), 4.04-3.94 (m, 1H), 3.93-3.81 (m, 3H), 3.76-3.54 (m, 9H), 3.52-3.43 (m, 3H), 3.43-3.37 (m, 1H), 3.36-3.23 (m, 2H), 1.91 (quin, *J* = 6.4 Hz, 2H), 1.60 (br quin, 2H), 1.34 (br s, 14H), 0.94 (t, *J* = 6.9 Hz, 3H); ¹³**C NMR** (75 MHz, CD₃OD): δ 104.6, 103.1, 81.4, 77.9, 76.7, 75.2, 74.9, 74.8, 74.3, 72.2, 71.6, 68.9, 68.1, 62.9, 62.3, 33.2, 31.2, 30.9, 30.8, 30.7, 30.6, 27.4, 23.9, 14.6; **HRMS (ESI)**: calcd. for C₂₄H₄₆O₁₂Na [M+Na]⁺ 549.2882, found 549.2874.

SUPPLEMENTARY REFERENCES

- 1 Ashton, P.R., Boyd, S.E., Brown, C.L., Jayaraman, N., Nepogodiev, S.A. & Stoddart, J.F. A convergent synthesis of carbohydrate-containing dendrimers. *Chem. Eur. J.* **2**, 1115-1128 (1996).
- 2 Virta, P., Leppaenen, M. & Loennberg, H. Pentaerythrityltetramine scaffolds for solid-phase combinatorial chemistry. *J. Org. Chem.* **69**, 2008-2016 (2004).
- 3 Nishizono, N., Sugo, M., Machida, M. & Oda, K. Synthesis of thietane nucleosides by glycosidation of thietanose derivatives with nucleobases *Tetrahedron* **63**, 11622-11625 (2007).
- Kim, Y.S., Kane, R.R., Beno, C.L., Ropmano, S., Mendez, G. & Hawthorne, M.F. Synthesis of new building blocks for boron-rich oligomers in boron neutroncapture therapy (BNCT). II: monomers derived from 2,2-disubstituted-1,3-diols. *Tetrahedron Lett.* 36, 5147-5150 (1995).
- 5 Mihai, C., Kravchuk, A.V., Tsai, M.-D. & Bruzik, K.S. Application of brønstead-type LFER in the study of the phopolipase C mechanism. *J. Am. Chem. Soc.* **125**, 3236-3242 (2003).